S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
S&P 500   5,047.77 (-0.28%)
DOW   37,771.67 (+0.10%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
Free Trial

ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)
Free acad Stock Alerts
$17.05
+0.16 (+0.95%)
(As of 10:52 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 13Estimated
Actual EPS
(Feb. 27)
$0.28 Missed By -$0.04
Consensus EPS
(Feb. 27)
$0.32
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

ACAD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ACAD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ACADIA Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.01)$0.12$0.06 
Q2 20243$0.17$0.26$0.20 
Q3 20243$0.17$0.27$0.22 
Q4 20243$0.18$0.33$0.24 
FY 202411$0.51$0.98$0.72 
Q1 20251$0.30$0.30$0.30 
Q2 20251$0.22$0.22$0.22 
Q3 20251$0.21$0.21$0.21 
Q4 20251$0.21$0.21$0.21 
FY 20254$0.94$0.94 $0.94

ACAD Earnings Date and Information

ACADIA Pharmaceuticals last issued its quarterly earnings results on February 27th, 2024. The biopharmaceutical company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.32 by $0.04. The business had revenue of $231.04 million for the quarter, compared to the consensus estimate of $223.79 million. Its revenue for the quarter was up 69.3% compared to the same quarter last year. ACADIA Pharmaceuticals has generated ($0.38) earnings per share over the last year (($0.38) diluted earnings per share). Earnings for ACADIA Pharmaceuticals are expected to grow by 88.89% in the coming year, from $0.63 to $1.19 per share. ACADIA Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off prior year's report dates.

ACADIA Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/13/2024
Estimated)		------- 
2/27/2024Q4 2023$0.32$0.28($0.04)$0.28$223.79 million$231.04 million    
11/2/2023Q3 2023($0.43)($0.40)+$0.03($0.40)$194.40 million$211.70 million
8/2/2023Q2 2023($0.12)$0.01+$0.13$0.01$163.86 million$165.20 million    
5/8/2023Q1 2023($0.21)($0.27)($0.06)($0.27)$120.29 million$118.46 million    
2/27/2023Q4 2022($0.25)($0.26)($0.01)($0.26)$135.18 million$136.49 million    
11/2/2022Q3 2022($0.18)($0.17)+$0.01($0.17)$139.04 million$130.70 million    
8/8/2022Q2 2022($0.25)($0.21)+$0.04($0.21)$130.06 million$134.56 million    
5/4/2022Q1 2022($0.49)($0.70)($0.21)($0.70)$122.22 million$115.47 million    
2/28/2022Q4 2021($0.24)($0.27)($0.03)($0.27)$135.44 million$130.80 million    
11/8/2021Q3 2021($0.26)($0.09)+$0.17($0.09)$127.77 million$131.61 million    
8/3/2021Q2 2021($0.30)($0.27)+$0.03($0.27)$124.94 million$115.22 million    
5/4/2021Q1 2021($0.53)($0.42)+$0.11($0.42)$112.91 million$106.55 million  

ACADIA Pharmaceuticals Earnings - Frequently Asked Questions

When is ACADIA Pharmaceuticals's earnings date?

ACADIA Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off last year's report dates. Learn more on ACAD's earnings history.

Did ACADIA Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) missed the analysts' consensus estimate of $0.32 by $0.04 with a reported earnings per share (EPS) of $0.28. Learn more on analysts' earnings estimate vs. ACAD's actual earnings.

How can I listen to ACADIA Pharmaceuticals's earnings conference call?

The conference call for ACADIA Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read ACADIA Pharmaceuticals's conference call transcript?

The conference call transcript for ACADIA Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does ACADIA Pharmaceuticals generate each year?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded annual revenue of $726.44 million.

How much profit does ACADIA Pharmaceuticals generate each year?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded net income of -$61.29 million. ACAD has generated -$0.38 earnings per share over the last four quarters.

What is ACADIA Pharmaceuticals's EPS forecast for next year?

ACADIA Pharmaceuticals's earnings are expected to grow from $0.63 per share to $1.19 per share in the next year, which is a 88.89% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:ACAD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings
The #1 Crypto for 2024
InvestorPlace